News from qualigen, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 26, 2021, 09:00 ET Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...

Jan 05, 2021, 09:00 ET Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...

Dec 22, 2020, 09:00 ET Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...

Dec 18, 2020, 15:07 ET Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single...

Dec 16, 2020, 10:25 ET Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single...

Dec 15, 2020, 09:00 ET Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...

Dec 08, 2020, 09:00 ET Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...

Dec 02, 2020, 09:00 ET Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final...

Nov 13, 2020, 09:00 ET Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter to...

Nov 05, 2020, 09:00 ET Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of...

Oct 28, 2020, 09:00 ET Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced receipt of written feedback to its Type B Pre-IND (Pre-Investigational New Drug...

Oct 08, 2020, 09:00 ET Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces it has entered into an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to...

Oct 01, 2020, 09:00 ET Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announces it has entered into an amended Sponsored Research Agreement with the University of Louisville...

Sep 17, 2020, 09:00 ET Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces its and the University of Louisville's joint filing of a United States provisional patent...

Aug 31, 2020, 09:00 ET Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with IRISYS LLC for the production of AS1411, Qualigen's lead...

Aug 28, 2020, 08:00 ET Qualigen Therapeutics Appoints Amy Broidrick to its Board of Directors

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today the addition of pharmaceutical executive Amy Broidrick to the company's Board of Directors....

Aug 14, 2020, 17:24 ET Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) today announced business highlights and financial results for the fiscal year...

Aug 06, 2020, 15:59 ET Qualigen Therapeutics to Host Business Update Conference Call on August 18, 2020

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that it will host a business update conference call and live...

Aug 04, 2020, 16:05 ET Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced the closing of its previously announced registered direct...

Jul 30, 2020, 08:00 ET Qualigen Therapeutics Begins Shipping FastPack® COVID-19 Antibody Test

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today it has begun commercial shipments of its FastPack® SARS-CoV-2...

Jul 22, 2020, 08:00 ET Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today the signing of an exclusive worldwide license agreement with the ...

Jul 13, 2020, 08:00 ET Qualigen Therapeutics CEO Issues Letter to Stockholders

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), announced that today Chief Executive Officer Michael Poirier has issued a...

Jul 10, 2020, 16:05 ET Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced the closing of its previously announced registered direct...

Jul 08, 2020, 17:19 ET Qualigen Therapeutics, Inc. Announces $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single...

Jul 07, 2020, 08:00 ET Qualigen Therapeutics Engages NFL Hall of Famer Mike Haynes as Advisor to the Company and Spokesman for the FastPack® Rapid Diagnostic System "Which Saved My Life"

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has engaged Pro Football Hall of Fame and College Football Hall ...